China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223). Yuyue Med will supply Frontier Bio the atomizer of the designated model used in the early clinical trials of the FB2001 atomized inhalant bofutrelvir at a discounted price, alongside relevant services. Meanwhile, Yuyue Med will provide “drug and device” regulatory filing support for the product. No financial details were disclosed.
FB2001: COVID-19 Treatment and Collaboration
FB2001, a COVID-19 3CL protease inhibitor co-developed by the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology, is used to treat mild and common novel coronavirus (SARS-CoV-2) infection, and to prevent SARS-CoV-2 exposure/infection. Previously, FB2001 performed well in combination with the clinical use of Yuyue Med’s atomizer in the early clinical trial, with the characteristics of high delivery volume, good stability, portability, practicality, and convenience.
Clinical Trial Progress
The FB2001 atomized inhalant bofutrelvir has obtained the go-ahead for a Phase II/III clinical study in moderate, common COVID-19 infections.-Fineline Info & Tech
